Samsung Bioepis and Genentech Settles Patent Dispute of Trastuzumab Biosimilar-Ontruzant

Samsung Bioepis and Genentech Settles Patent Dispute of Trastuzumab Biosimilar-Ontruzant

Shots:

  • Samsung Bioepis and Genentech has filed a joint stipulation of dismissal of their BPCIA patent litigation for Ontruzant, a biosimilar of Herceptin
  • Under the settlement and license agreement, the companies jointly moved to voluntarily dismiss Bioepis’ appeal of the PTAB’s decisions upholding the patentability of U.S. Patent nos. 6,627,196 & 7,371,379, directed to cancer therapies. The agreement allows Bioepis to commercialize the Ontruzant in the US
  • Ontruzant is biosimilar of trastuzumab targeting HER2 receptor, indicated for HER2-overexpressing breast cancer and m-gastric cancer marketed by Merck in the US and has received approval in the US & EU in Nov’2017 & Jan’2019 respectively

Click here to read full press release/ article | Ref: US District Court | Image: SBS